Business Context and Reporting Period
This Form 8-K was filed by ADVENTRX Pharmaceuticals, Inc. on November 15, 2005. The report discloses the entry into a definitive material agreement with Pharm-Olam International Ltd. regarding clinical trial services.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement rather than financial performance data.
Material Changes and Agreements
On November 15, 2005, the Company executed a "Clinical Protocol Agreement" with Pharm-Olam International Ltd., effective March 29, 2005. Under this agreement, Pharm-Olam was engaged to:
- Set up and monitor trial sites for the Company's European Union-based CoFactor Phase IIb trial for metastatic colorectal cancer.
- Perform product assessment.
- Conduct the Phase IIb Trial.
- Provide other clinical research organization services.
Pharm-Olam is required to apply quality control systems to ensure compliance with the study protocol, good clinical practice, and applicable regulatory requirements.
Termination Provisions and Risks
The agreement includes specific termination clauses:
- Material Breach: Either party may terminate if a material breach is not cured within 30 days of notice.
- Patient Interest: Termination is permitted if independent medical advice indicates it is in the best interests of patients.
- Serious Adverse Event: The Company may terminate with 60 days' notice in the event of a serious adverse event.
- Convenience: The agreement may not be terminated for convenience.
Investor Verification Checklist
- Verify the status and enrollment progress of the CoFactor Phase IIb trial for metastatic colorectal cancer.
- Confirm the total financial obligations and payment terms associated with the Clinical Protocol Agreement, which are not detailed in this filing.
- Monitor for any reports of serious adverse events that could trigger the 60-day termination clause.
- Review subsequent filings for updates on the trial's completion or any amendments to the agreement with Pharm-Olam.